BioInformant

Your Global Leader in Stem Cell Market Research

Home » Cord Blood » Page 3

100+ Current and Future Uses of Umbilical Cord Stem Cells

By

Umbilical cord stem cells are present within the cord that connects a newborn to its mother and uses of these birth cells include treating cancers, diseases, injuries, and more. Umbilical cord blood contains hematopoietic stem cells (HSCs), which are multipotent stem cells that can give rise to other blood and immune system cells.

Stem cells can also be collected from a newborn’s:

  • Umbilical cord tissue (Wharton’s jelly)
  • Placenta
  • Amnion

Most commonly, hematopoietic stem cells (HSCs) from cord blood are used to treat blood cancers, such as leukemia. When compared to hematopoietic stem cells from genetically matched bone marrow donor, cord blood HSCs may provide some medical advantages, including fewer immune system complications, such as graft-versus-host disease (GvHD).

In recent years, regenerative medicine has continued to increase the list of medical uses for stem cells from umbilical cord. Find out more about current and future uses of umbilical cord stem cells below.

In this article:

  1. Current Uses of Stem Cells
  2. Potential Uses for Stem Cells

[Read more…]

Magenta Therapeutics Awarded an FDA RMAT for MGTA-456

By

On September 4, 2019, Magenta Therapeutics announced it had received an FDA Regenerative Medicine Advance Therapy (RMAT) designation for MGTA-456, an expanded CD34+ cell therapy treatment used in place of single umbilical cord blood (UCB) transplantation. This one-time stem cell treatment is being investigated for the treatment of multiple inherited metabolic disorders. While there are 36 publicly announced RMAT designations, the FDA states that 40 or more have been awarded to date. [Read more…]

RoosterBio Launches the Only Umbilical Cord hMSC System in the World Designed for Perinatal Cell Therapy Product Development

By

RoosterBio, Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, released the Regenerative Medicine industry’s first human umbilical cord (hUC) MSC paired cell and media system designed for product development and bringing with it an unprecedented step-change in quantifiable productivity metrics. RoosterVial™-hUC-MSC-XF, allows scientists to generate billions of perinatal cells in a fraction of the time when paired with RoosterBio’s existing xeno-free (XF) hMSC plug and play systems. This product line is the only commercially available, high-volume perinatal MSC bioprocess system with a line of sight to towards clinical translation. [Read more…]

What are Placental Stem Cells? | What are Placental Stem Cells Used For?

By

What are placental stem cells and what are placental stem cells used for? As placental stem cells get explored for a variety of therapeutic applications, these questions become increasingly important. The opportunity to collect placental stem cells is also a once in a lifetime opportunity. [Read more…]

Cord Blood Market Consolidation in Latin America

By

CryoHoldcoIn this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco.

Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America.

CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. In this interview, we discuss the current and future state of cord blood banking within Latin America, Cryoholdco’s role within this evolving marketplace, and future directions for the company.

Prior to initiating the consolidation strategy of CryoHoldco with ACON Investments, Alexis was a Director of TCP Latam, a private equity and restructuring fund in Brazil.  Prior to TCP Latam, he was a senior associate at Long Point Capital, a leveraged-buyout private equity fund in New York, where Alexis was responsible for equity investments in excess of USD $100 million in several private companies.

[Read more…]

BioInformant's World-Class Clients